The following video is part of our "Motley Fool Conversations" series, in which health care editor/analyst David Williamson discusses topics from across the investing world.
This video takes a closer look at Amarin, which has been on a tear lately, up 40% over the last 3 months. While some may think this run is overblown, Amarin has a lot going for it. David highlights three important drivers for the company and why Wall Street is right in predicting big things for the small company.
Health care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health care company that he believes is poised for monster returns. To uncover this top pick today, enjoy our special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
David Williamson owns shares of Amarin. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Growth Stocks to Own in 2018
If you're looking for outstanding growth vehicles to own next year, these three biotech stocks are worth checking out.
3 Small-Cap Biotech Stocks That Could Be Big Winners in 2018
If you're on the hunt for small-cap biotechs that could be big winners next year, Amarin, MannKind Corp., and 22nd Century Group need to be on your radar right now.
Here's Why Amarin Corporation plc Is on the Rise Today
Second-quarter Vascepa sales were even better than expected.